MaaT Pharma
A Lyon-based pioneer in high-diversity microbial ecosystems for oncology; lead drug MaaT013 reached pivotal phase 3 in Europe for acute graft-versus-host disease with an automated GMP plant.
- Country
- France
- Ticker
- EPA:ALMAAT
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Microbiome therapeutics (live biotherapeutic products) | therapeutics-platforms | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.